Comparison of effects of Dapagliflozin and Linagliptin in treatment of obese patients with type 2 diabetes mellitus
Objective:To compare effects of Dapagliflozin and Linagliptin in treatment of obese patients with type 2 diabetes mellitus(T2DM).Methods:The clinical data of 90 obese patients with T2DM admitted to this hospital from June 2020 to April 2023 were retrospectively analyzed.According to different treatment options,they were divided into control group and observation group,45 cases in each group.Both groups were treated with Metformin.On this basis,the control group was treated with Linagliptin,while the observation group was treated with Dapagliflozin.The levels of blood glucose[fasting blood glucose(FPG),2 h postprandial blood glucose(2hPG)],lipid metabolism indexes[high-density lipoprotein cholesterol(HDL-C),low-density lipoprotein cholesterol(LDL-C),total cholesterol(TC),triacylglycerol(TG)]and serum adipokines[cyclic adenosine monophosphate response element binding protein regulated transcription coactivator 3(CRTC3),human neuropeptide(Spexin)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:After the treatment,the levels of FPG and 2hPG in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the HDL-C levels of the two groups were higher than those before the treatment,and that in the observation group was higher than that in the control group;the levels of LDL-C,TC and TG in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;and the differences were statistically significant(P<0.05).After the treatment,the serum CRTC3 levels of the two groups were lower than those before the treatment,and that in the observation group was lower than that in the control group;the levels of Spexin in the two groups were higher than those before the treatment,and that in the observation group was lower than that in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Dapagliflozin combined with Metformin in the treatment of the obese patients with T2DM can reduce the blood glucose levels and improve the lipid metabolism indexes and serum adipokine levels.Moreover,it is superior to Linagliptin combined with Metformin treatment.
NETL
NSTL
万方数据
